Demand for Genentech's highly successful drugs, such as Avastin, has
caused the company to operate at near-capacity and has led the company to cancel a separate deal with Amgen
to manufacture that
firm's products. Genentech's senior vice president of product
operations said he does not like operating at capacity "for an
extended period of time," but the company's plan is to do that for some
time, while making additional operational capacity available.

Full Story:

Related Summaries